Thrombotic Thrombocytopenic Purpura Clinical Trial
Official title:
A Randomized, Double-blind, Placebo Controlled, Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy
The purpose of this ascending-dose research study is to determine whether the administration of ARC1779 Injection improves subject's health profile by protecting the brain, heart, and kidney from damage due to formation of small blood clots in blood vessels. It will also determine the safety of ARC1779 Injection, how ARC1779 Injection enters and leaves the blood and tissue over time, and its effect on laboratory tests related to blood clotting, heart and brain function, and other body systems.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
Recruiting |
NCT05785468 -
A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)
|
||
Completed |
NCT04074187 -
A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
|
Phase 2/Phase 3 | |
Terminated |
NCT00953771 -
Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)
|
Phase 2 | |
Recruiting |
NCT01257269 -
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
|
||
Not yet recruiting |
NCT05568147 -
Aspirin for Prophylaxis of TTP
|
Phase 2/Phase 3 | |
Recruiting |
NCT05468320 -
Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
|
Phase 3 | |
Completed |
NCT00713193 -
Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)
|
Phase 3 | |
Completed |
NCT00426686 -
ADAMTS13 in Thrombotic Thrombocytopenic Purpura
|
N/A | |
Withdrawn |
NCT00251277 -
Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura
|
Phase 1/Phase 2 | |
Recruiting |
NCT04588194 -
Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
|
Phase 2 | |
Active, not recruiting |
NCT03237819 -
Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care
|
Phase 3 | |
Completed |
NCT00907751 -
Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura
|
Phase 2 | |
Completed |
NCT03369314 -
Observational Study of the Use of octaplasLG®.
|
||
Terminated |
NCT01938404 -
Octaplas Adult TTP Trial
|
||
Recruiting |
NCT04981028 -
The ConNeCT Study: Neurological Complications of TTP
|
||
Completed |
NCT02134171 -
Early Predictive Factors of Cardiac and Cerebral Involvement in TMA
|
N/A | |
Recruiting |
NCT05389007 -
.German TTP-Registry (Thrombotic Thrombocytopenic Purpura)
|
||
Withdrawn |
NCT02626663 -
The Role of Microparticles as a Biomarker
|
||
Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|